Published in Diabetologia on September 01, 2009
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes (2010) 3.77
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia (2011) 3.52
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Risk of cancer following hospitalization for type 2 diabetes. Oncologist (2010) 1.75
Diabetes and pancreatic cancer. Mol Carcinog (2012) 1.71
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol (2010) 1.61
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord (2010) 1.60
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One (2010) 1.54
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care (2011) 1.52
Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol (2010) 1.31
Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. PLoS One (2011) 1.31
Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid (2011) 1.22
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care (2012) 1.22
Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol (2011) 1.20
Metformin in cancer prevention and therapy. Ann Transl Med (2014) 1.18
Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes (2010) 1.13
Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab (2013) 1.11
Gerosuppressant metformin: less is more. Aging (Albany NY) (2011) 1.08
Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond) (2009) 1.06
Diabetes and cancer: is diabetes causally related to cancer? Diabetes Metab J (2011) 1.06
Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf (2013) 1.05
Risk of cancer in diabetes: the effect of metformin. ISRN Endocrinol (2013) 1.04
Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2. PLoS One (2012) 1.03
Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol (2010) 1.02
Diabetes and thyroid cancer risk: literature review. Exp Diabetes Res (2012) 1.02
Latest insights into the risk of cancer in diabetes. J Diabetes Investig (2013) 1.01
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat (2011) 1.01
Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas (2013) 1.00
Interpreting adverse signals in diabetes drug development programs. Diabetes Care (2013) 0.99
Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues. Diabetologia (2009) 0.94
Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? Diabetologia (2010) 0.93
Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care (2013) 0.89
Insulin glargine: a reevaluation of rodent carcinogenicity findings. Int J Toxicol (2012) 0.88
Pioglitazone: Indian perspective. Indian J Endocrinol Metab (2011) 0.88
Diabetes and gastric cancer: the potential links. World J Gastroenterol (2014) 0.88
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia (2012) 0.88
Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes. Diabetologia (2009) 0.88
Increased cancer incidence risk in type 2 diabetes mellitus: results from a cohort study in Tyrol/Austria. BMC Public Health (2014) 0.88
The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord (2009) 0.86
The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem (2013) 0.86
Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One (2012) 0.85
Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts. PLoS One (2013) 0.85
Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open (2012) 0.84
Insulin analogs and cancer. Front Endocrinol (Lausanne) (2012) 0.83
Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive. Nat Rev Endocrinol (2013) 0.83
Diabetes mellitus and gastric carcinoma: Is there an association? J Carcinog (2011) 0.82
Insulin glargine controversy: a tribute to the editorial team at Diabetologia. Diabetes (2009) 0.82
Diabetes, insulin treatment, and cancer risk: what is the evidence? F1000 Med Rep (2010) 0.82
Supramolecular protein engineering: design of zinc-stapled insulin hexamers as a long acting depot. J Biol Chem (2010) 0.82
Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PLoS One (2013) 0.81
Increased cancer mortality in diabetic people treated with insulin: a register-based follow-up study. BMC Health Serv Res (2013) 0.80
Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma. BMC Res Notes (2013) 0.79
A Salutary Tale-Glargine insulin and cancer risk. Ecancermedicalscience (2009) 0.78
Biomarkers of the metabolic syndrome and breast cancer prognosis. Cancers (Basel) (2010) 0.78
Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. Elife (2016) 0.78
[Insulin therapy of diabetes]. Wien Klin Wochenschr (2012) 0.78
Insulin concerns and promises. Diabetes Care (2011) 0.78
Comment on: Morden et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011;34:1965-1971. Diabetes Care (2012) 0.77
A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues. Carcinogenesis (2015) 0.77
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. J Clin Med (2014) 0.76
Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. Diabetes Metab Syndr Obes (2010) 0.76
Insulin receptor membrane retention by a traceable chimeric mutant. Cell Commun Signal (2013) 0.75
The evolving world of GLP-1 agonist therapies for type 2 diabetes. Ther Adv Endocrinol Metab (2010) 0.75
Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes. Diabetes Ther (2017) 0.75
Current therapeutic agents and anesthetic considerations for diabetes mellitus. Korean J Anesthesiol (2012) 0.75
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism. Sci Rep (2016) 0.75
Cancer incidence in persons with type 1 diabetes: a five-country study of 9,000 cancers in type 1 diabetic individuals. Diabetologia (2016) 0.75
Uncertain risks of drug related harms, the precautionary principle and limitations of meta-analysis. Br J Clin Pharmacol (2009) 0.75
Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study. Sci Rep (2016) 0.75
Islet inflammation and ductal proliferation may be linked to increased pancreatitis risk in type 2 diabetes. JCI Insight (2017) 0.75
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis. Diabetes Ther (2017) 0.75
[Insulin therapy of diabetes]. Wien Klin Wochenschr (2016) 0.75
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest (1983) 4.70
Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia (2005) 3.65
Structure of Rhodopseudomonas sphaeroides R-26 reaction center. FEBS Lett (1986) 3.28
The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia (2009) 3.05
Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia (2010) 2.71
A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol (1987) 2.63
Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med (1990) 2.25
Congenital rubella: citation virus or viral cause of type 1 diabetes? Diabetologia (2008) 2.17
Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia (2007) 2.16
Smoking induces insulin resistance--a potential link with the insulin resistance syndrome. J Intern Med (1993) 2.01
Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet (1979) 2.01
Diet, delusion and diabetes. Diabetologia (2009) 1.87
To boldly go--or to go too boldly? The accelerator hypothesis revisited. Diabetologia (2007) 1.79
Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A (1997) 1.73
Phycocyanobilin. Structure and exchange studies by nuclear magnetic resonance and its mode of attachment in phycocyanin. A model for phytochrome. Biochemistry (1968) 1.67
Evidence for lactate production by human adipose tissue in vivo. Diabetologia (1990) 1.63
Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia (2006) 1.60
The organization and myofilament array of insect visceral muscles. J Cell Sci (1966) 1.57
Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia (2007) 1.56
Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun (2001) 1.54
The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients--the EUGENE2 study. Diabetologia (2008) 1.53
Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes (1996) 1.52
Lipid intolerance in smokers. J Intern Med (1995) 1.48
Angiotensin I: metabolism by plasma membrane of lung. Science (1972) 1.45
Isolation and characterization of cells from rat adipose tissue developing into adipocytes. J Lipid Res (1978) 1.43
Insulin resistance with low cellular IRS-1 expression is also associated with low GLUT4 expression and impaired insulin-stimulated glucose transport. FASEB J (2001) 1.41
Electron microscopy of endothelial and epithelial components of the lungs: correlations of structure and function. Fed Proc (1973) 1.40
Fat cell metabolism in different regions in women. Effect of menstrual cycle, pregnancy, and lactation. J Clin Invest (1985) 1.40
Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab (1999) 1.37
Characterization by microdialysis of intracellular glucose level in subcutaneous tissue in humans. Am J Physiol (1988) 1.30
Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med (1991) 1.30
Counter-regulation of insulin-stimulated glucose transport by catecholamines in the isolated rat adipose cell. J Biol Chem (1984) 1.29
Body fat and adipose tissue cellularity in infants: a longitudinal study. Metabolism (1977) 1.28
Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes (2003) 1.28
Regional adipose tissue cellularity in relation to metabolism in young and middle-aged women. Metabolism (1975) 1.28
Smoking cessation improves insulin sensitivity in healthy middle-aged men. Eur J Clin Invest (1997) 1.27
Exocytosis in the adrenal medulla demonstrated by freeze-etching. Science (1973) 1.25
Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia (2008) 1.25
Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia (2008) 1.25
Metabolism of adenosine 5'-monophosphate during circulation through the lungs. Trans Assoc Am Physicians (1971) 1.25
Glycerol production in subcutaneous adipose tissue in lean and obese humans. J Clin Invest (1992) 1.24
Endothelial projections as revealed by scanning electron microscopy. Science (1971) 1.24
Effect of beta-adrenoceptor blockade on exercise performance and metabolism. Clin Sci (Lond) (1981) 1.23
Comparison of two methods for determining human adipose cell size. J Lipid Res (1972) 1.23
Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun (2003) 1.23
Regional differences and effect of weight reduction on human fat cell metabolism. Eur J Clin Invest (1979) 1.22
Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion. Br Med J (Clin Res Ed) (1983) 1.22
A rapid, simple method for isolating pinocytotic vesicles and plasma membrane of lung. Biochim Biophys Acta (1971) 1.19
Differences in metabolic responses to beta-adrenergic stimulation after propranolol or metoprolol administration. Acta Med Scand (1979) 1.18
Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation (1996) 1.17
Glucose uptake in human adipose tissue. Metabolism (1987) 1.15
Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes (1990) 1.14
Characterization of bacterial photosynthetic reaction center crystals from Rhodopseudomonas sphaeroides R-26 by X-ray diffraction. J Mol Biol (1985) 1.14
Declassifying diabetes. Diabetologia (2006) 1.14
Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism (1990) 1.12
Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia (2012) 1.11
Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB J (1999) 1.11
Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes (1999) 1.11
Order! Order! Order in the House! DIAMAP: a road map for European diabetes research. Diabetologia (2008) 1.11
Cellularity in different regions of adipose tissue in young men and women. Metabolism (1972) 1.10
Cancer and diabetes: are we ready for prime time? Diabetologia (2010) 1.10
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia (2012) 1.09
Effect of cell size on lipolysis and antilipolytic action of insulin in human fat cells. J Lipid Res (1972) 1.08
Metabolism of [8-L-[14C] phenylalanine]-angiotensin I in the pulmonary circulation. Biochem J (1971) 1.07
AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia (2010) 1.07
The insulin resistance syndrome and postprandial lipid intolerance in smokers. Atherosclerosis (1997) 1.07
[An extensive study gives a hope for better control of type 2 diabetes mellitus]. Lakartidningen (1998) 1.07
The insulin resistance syndrome in smokers is related to smoking habits. Arterioscler Thromb (1994) 1.07
Regional adipose tissue metabolism in men and postmenopausal women. Int J Obes (1987) 1.06
Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia (2004) 1.06
Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007*. Diabet Med (2010) 1.06
Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med (1999) 1.05
The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids (2005) 1.05
Effect of cell size on lipid synthesis by human adipose tissue in vitro. J Lipid Res (1971) 1.05
Effects of hyperglycemia on interdigestive gastrointestinal motility in humans. Scand J Gastroenterol (1994) 1.05
Insulin resistance in fat cells from obese Zucker rats--evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4. Mol Cell Biochem (2000) 1.04
Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia (2012) 1.03
Freeze-etch studies of the plasma membrane of pulmonary endothelial cells. J Cell Biol (1973) 1.03
Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis (2008) 1.02
Collateral damage: the conundrum of drug safety. Diabetologia (2009) 1.02
Insulin binding and responsiveness in fat cells from patients with reduced glucose tolerance and type II diabetes. Diabetes (1983) 1.02
Human adipose tissue in culture. VIII. Studies on the insulin-antagonistic effect of glucocorticoids. Metabolism (1979) 1.01
The toxicity of streptolysin O for beating mammalian heart cells in tissue culture. J Exp Med (1970) 1.00
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab (2011) 1.00
Freeze-fractured lamellar body membranes of the rat lung great alveolar cell. Tissue Cell (1972) 1.00
Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest (2007) 0.98
Lactate release from the subcutaneous tissue in lean and obese men. J Clin Invest (1994) 0.98
The big fat bariatric bandwagon. Diabetologia (2010) 0.97
Nice insulins, pity about the evidence. Diabetologia (2007) 0.97
Fatty acids in the portal vein of the rat regulate hepatic insulin clearance. J Clin Invest (1991) 0.97
Quantitation of different cells in the epididymal fat pad of the rat. J Lipid Res (1979) 0.96
Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis. Diabetologia (2009) 0.96
Microdialysis of intercellular adenosine concentration in subcutaneous tissue in humans. Am J Physiol (1989) 0.95
Identification of novel TYR and TYRP1 mutations in oculocutaneous albinism. Clin Genet (2005) 0.94
Morphologic studies of human subcutaneous adipose tissue in vitro. Anat Rec (1971) 0.94
Possible systemic metabolic effects of regional adiposity in a patient with Werner's syndrome. Int J Obes (1980) 0.94
Effect of free fatty acids on insulin receptor binding and tyrosine kinase activity in hepatocytes isolated from lean and obese rats. Diabetes (1992) 0.93
Studies on the insulin-antagonistic effect of catecholamines in normal man. Evidence for the importance of beta 2-receptors. Diabetologia (1986) 0.93
Nicotine infusion acutely impairs insulin sensitivity in type 2 diabetic patients but not in healthy subjects. J Intern Med (2001) 0.93